SBIR/STTR Research Award

Innate Immune Stimulation as a Pathogen Countermeasure

Award identifier 939564e1ff0f78d6bfcff78202747fe58de4e355d9c8d77fdb6c8db017835537Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$975,860

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
JUVARIS BIOTHERAPEUTICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The overall purpose of this project is to investigate and develop a novel immune stimulant that can be used to elicit non-specific protection against pathogenic microorganisms that might be deployed in bioterrorist attacks. The product, comprised of cationic liposome-plasmid DNA complexes (CLDC), is an extremely potent stimulus for activation of innate immunity, particularly for release of interferons and other cytokines. The major advantages of CLDC relative to conventional immunostimulants are that they are more potent activators of interferon release, they can be administered by aerosol or mucosal delivery, they can be lyophilized and retain activity, and they are relatively simple and inexpensive to manufacture. The proposed studies are designed to test the hypothesis that CLDC can rapidly elicit sufficient protective innate immunity to be efficacious after parenteral or mucosal in an aerosol bacterial challenge rodent model. In preliminary studies, we have observed potent activation of innate immunity after administration of CLDC and efficacy after aerosol challenge with Mycobacterium tuberculosis. Complete protection has also been observed following intraperitoneal and intranasal administration of CLDC 48 hours prior to lethal intranasal challenge with Francisella tularensis LVS. We will, therefore, examine the effectiveness of CLDC-mediated immune activation by other routes of administration, particularly after mucosal delivery to the lungs and upper airways to evaluate protection against aerosol challenge with the more pathogenic F. tularensis Schu4. The specific goals of this project are (1) to determine how the route of administration and dosing regimen of CLDC affects the magnitude, quality, and duration of innate immune activation, and (2) determine the impact of CLDC-induced immunity on protection against F. tularensis challenge. We believe these studies will provide the basis for the CLDC' ability, in an easily administered format, to rapidly activate potent and consistent innate immune responses that will be essential in biodefense and civilian applications.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.